Harvard Medical School-ko ikertzaileekin lankidetzan egindako argitalpenak (36)

2024

  1. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

    Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

  2. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  3. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 112-131

  4. Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism: A Randomized Trial

    Chest, Vol. 165, Núm. 3, pp. 673-681

  5. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  6. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

  7. Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial

    Archivos de Bronconeumologia, Vol. 60, Núm. 7, pp. 417-422

2023

  1. Cardiac Progenitor Cell Exosomal miR-935 Protects against Oxidative Stress

    Cells, Vol. 12, Núm. 18

  2. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

  2. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

    Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3537-3545

  3. COPD detection in lung cancer screening programmes: “hitting two birds with one stone”

    European Respiratory Journal

  4. Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort

    Respirology, Vol. 27, Núm. 4, pp. 286-293

  5. Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease

    Respiratory Research, Vol. 23, Núm. 1

  6. Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model

    Frontiers in Cardiovascular Medicine, Vol. 9

  7. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  8. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

    Chest, Vol. 161, Núm. 2, pp. 524-534

  9. Inhaled corticosteroids, COPD, and the incidence of lung cancer: a systematic review and dose response meta-analysis

    BMC Pulmonary Medicine, Vol. 22, Núm. 1

  10. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis

    Hepatology, Vol. 75, Núm. 4, pp. 968-982

  11. Severe exacerbations and mortality in COPD: Importance of both body and mind

    Respirology